Janssen Collaborates with Iktos for its Artificial Intelligence (AI) Technology

Shots:

• Janssen enters into an agreement to utilize Iktos’ AI (in silico drug design) technology for the enhancement of speed & efficacy of its small molecules discovery platform and will develop new therapies utilizing Iktos’ know-how in deep generative models applied to chemistry with its own AI expertise
• Additionally, Iktos has also collaborated with other biopharma companies for its AI technology to expedite the design of compounds and plans to release its SaaS software Makya, a beta version for testing by customers in mid-2019
• Iktos’ in silico drug design technology improves the drug discovery workflows by utilizing the existing data in designing molecules that are optimized in silico to meet the criteria of a small molecule discovery projects

Click here to read full press release/ article | Ref: Business Wire | Image: Abyss